Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Pfizer

More ‘discreet’ Viagra-type drug could soon be available in Britain

US company Viatris has applied for a UK trademark for wafer-like film that dissolves in the mouth

The Guardian - UK

"I’d love to see fewer boundaries in the design industry”: a day in the life of Amy Globus

Team's co-founder discusses approaching design with an artist's sensibility.

Creative Bloq

President-Elect Trump Hosts Pharmaceutical Ceos For Dinner At Mar-A-Lago

President-elect Trump's dinner with pharmaceutical executives and healthcare appointees highlights industry collaboration and healthcare challenges.

Top News

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer Stock: Is PFE Underperforming the Healthcare Sector?

Despite Pfizer's underperformance relative to the healthcare sector, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Pfizer's New Chief Scientific Officer Charts R&D Vision For High And Low-Risk Investments

Pfizer's Chris Boshoff outlines plans to prioritize high-return projects, with a focus on obesity, Oncology, and oral GLP-1 therapies, amid Q3 growth.

Benzinga

Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch

Here's why Eli Lilly, Pfizer, and AstraZeneca are biotech stocks worth considering, with strong pipelines and growth potential beyond vaccines.

MarketBeat

Is Biotech’s Bull Run Over? Examining Election Impacts

The biotech sector's breakout attempt post-election reversed sharply, with ETFs like IBB and XBI falling and invalidating the long-term bullish setup.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Pfizer Not Eligible To Recover $75 Million From Settlement With SEC

Judge ruled that Pfizer could not recover $75 million left over from insider trading SEC settlement.

International Business Times

The latest COVID booster will soon be available. Should I get one? Am I eligible?

Australia’s Therapeutic Goods Administration (TGA) has recently approved a new COVID booster. The shot was developed by Pfizer and targets the JN.1 sub-variant of Omicron.

The Conversation

ORIC: Working with Two Pharma Giants, Analysts See +100% Upside

ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about.

MarketBeat

Thursday's Unusual Options Activity Reveals 3 Promising Long-Term Investments

Thursday's trading session revealed 33 call options with unusually high activity and boasting expiration dates of 365 days or more. Three have emerged as promising long-term investments from this diverse pool of potential opportunities.

Barchart

Reasons to be hopeful: five ways science is making the world better

If Trump’s re-election is getting you down, these innovations in medicine and technology should cheer you up

The Guardian - UK

Don't wait for a holiday surge. Now is a good time to get your flu and COVID-19 vaccines

Health officials say it's important to get flu and COVID-19 vaccines ahead of the holidays when respiratory bugs tend to spread

The Independent UK

Is This High-Yield Dividend Stock a Buy After Earnings?

This pharmaceutical giant's Q3 numbers came in ahead of Street estimates.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Are Wall Street Analysts Predicting Pfizer Stock Will Climb or Sink?

Despite Pfizer’s underperformance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Kiplinger

Stock Market Today: Nasdaq Hits New High Ahead of Alphabet Earnings

The Google parent is one of several mega caps reporting earnings this week, with results due out after Tuesday's close.

Kiplinger

Why Pfizer Stock Is Lower After a Beat-and-Raise Quarter

Pfizer stock is down Tuesday even after the drugmaker reported higher-than-expected Q3 earnings and raised its full-year outlook.

The Independent UK

Hundreds of blood cancer patients to benefit from new Pfizer treatment

Myeloma affects 24,000 people a year in the UK

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Stock Index Futures Tread Water Ahead of U.S. JOLTs Report, Alphabet Earnings on Tap

December S&P 500 E-Mini futures (ESZ24) are up +0.06%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.08% this morning as market participants geared up for the latest reading on U.S. job openings while also awaiting a deluge of corporate earnings reports from heavyweight names.

The Guardian - UK

Gold price hits fresh record high, as bitcoin also rallies – as it happened

Analysts say gold is benefited from safe-haven demand amid persistent geopolitical tensions, expectations of monetary policy easing, and mounting uncertainty surrounding the US presidential election.

Fortune

As activist Starboard engages constructively, here’s a potent prescription for Pfizer’s future success under Dr. Bourla’s watch

Pfizer is getting back on track—but an even more potent prescription for success could be in the cards for the pharmaceutical giant under.

Barchart

What to Expect From Pfizer's Q3 2024 Earnings Report

Pfizer is expected to release its fiscal third-quarter earnings later this month, and analysts project a triple-digit profit growth.

Barchart

Should You Follow Activist Investors Into This High-Yield Dividend Stock?

This dividend stock is now on the radar of activist investors, with Starboard eyeing a possible management shakeup.

The Guardian - UK

‘The UK is at the back of the race of turtles’: Sanofi’s boss on the need to develop new medicines

Paul Hudson, the Briton in charge of the French drug firm, is a big believer in the potential of AI to transform healthcare

Barchart

How To Spot Good Value Stocks In A Sea Of Noise

Explore why traditional value investing often falls short and how catalysts can transform undervalued stocks into lucrative investments.

1 … 12 13 14 15

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.